Japanese drug regulatory authorities failed to make a decision on whether favipiravir (Avigan) would be used as a treatment for […]
A Kuwait-based clinical trial sponsored by Indian generic drug producer Dr. Reddy’s Laboratory was recently terminated as the resulting data […]
Yet another nation has opted to embrace the antiviral drug Favipiravir (Avigan) as a treatment for early onset COVID-19. Approved […]
Health Canada may be following India, Russia, some nations in Eastern Europe, and dozens of other nations who opt to […]
Japanese health authorities are struggling to reach a decision as to whether favipiravir (Avigan) is effective as treatment for COVID-19 […]
Publicly traded Appili Therapeutics out of Canada, a biotech venture attempting to commercialize Avigan® tablets (favipiravir), the antiviral drug originating […]
Glenmark Pharmaceuticals, a prominent Indian pharmaceutical firm, reports that the oral antiviral drug originating in Japan, Favipiravir, prevents the replication […]
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today […]
The Russian Federal Service for Surveillance in Healthcare recently announced the permanent registration of three drugs targeting COVID-19, all based […]
TrialSite reported that in Russia, the Ministry of Health approved the generic form of Favipiravir, the Japanese generic of the […]
